Skip to main content

FDA Approves Combo Meningitis Vaccine for Infants


June 14, 2012 — The US Food and Drug Administration (FDA) has approved a combination meningitis vaccine for infants and children aged 6 weeks through 18 months, the agency announced today.
The FDA said this is the first meningococcal vaccine that can be taken by children as young as 6 weeks of age.
The vaccine, called Menhibrix (GlaxoSmithKline Biologicals), immunizes against 2 types of bacteria: Neisseria meningitidis (serogroups C and Y) and Haemophilus influenzae type B (Hib). Each bacterium can infect the lining that surrounds the brain and spinal cord, according to the FDA.
Both meningococcal and Hib diseases can cause death or serious and permanent damage such as mental retardation and blindness. The diseases can progress rapidly, and their symptoms are hard to distinguish from those of other common childhood conditions, making them particularly dangerous for children younger than 2 years of age.
The FDA determined that Menhibrix is effective based on tests conducted with several hundred US infants and toddlers who received the vaccine. Their immune responses to the Hib component resembled those of infants and toddlers who received a vaccine against invasive Hib disease. Menhibrix also produced antibodies against the meningococcal component at levels, indicating that it would offer protection against meningococcal disease caused by serogroups C and Y of N meningitidis.
The vaccine’s safety was established by a study of roughly 7500 infants and toddlers in the United States, Mexico, and Australia. Pain, redness, and swelling at the injection site; irritability; and fever were common adverse reactions.
Menhibrix is administered in 4 doses at months 2, 4 and 6, with the fourth dose administered between months 12 and 16. The first dose can be given as early as 6 weeks, and the last as late as 18 months.

Comments

Post a Comment

Popular posts from this blog

Early Surgery for Sigmoid Volvulus May be Safe and Effective

August 29, 2012 — Early elective surgery for sigmoid volvulus should be encouraged because it is associated with lower morbidity and mortality, as well as a lower incidence of recurrence, than conservative treatment, according to the findings of a retrospective study. Omid Yassaie, MBChB, from Tauranga Hospital in New Zealand, and colleagues presented their findings in an article published online August 24 in the ANZ Journal of Surgery. The authors remark that the optimal treatment of sigmoid volvulus and the long-term prognosis of patients after treatment are unclear. "Sigmoidoscopic treatment has gained favour as it is less invasive than surgery; however, a significant portion of patients return with recurrent volvulus," the authors write. "There is little, if any data in New Zealand or Australia on long-term follow-up of sigmoid volvulus." The authors analyzed 57 patients (from a total of 84 admissions for sigmoid volvulus) who were admitted to the Department o…
Post a Comment
Read more

Secondary Prevention: Clinical Approaches to Managing the Higher-Risk Patient with Heart Disease

INCIDENCE/PREVALENCE/BURDENS ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD) The prevention of an initial and recurrent cardiovascular event and other complications, such as diabetes and kidney failure [also known as end-stage renal disease (ESRD) or chronic kidney disease (CKD) stage 5] is an important goal in patients with a history of CVD. Each year, approximately 185,000 Americans suffer a recurrent stroke, approximately 470,000 will have a recurrent coronary attack, and an estimated 325,000 will suffer a recurrent myocardial infarction.[1] Secondary prevention strategies offer the opportunity to prevent further complications and improve outcomes by early detection and management of common comorbidities. The burden on public health and the costs associated with chronic illnesses such as CVD, CKD, and diabetes remain high. An estimated 82.6 million American adults (1 in 3) have 1 or more types of CVD.[1] Heart failure is the fastest-growing clinical cardiac disease entity in the Unit…
Post a Comment
Read more

Sexsomnia: Clinical Analysis of an Underdiagnosed Parasomnia

Introduction Sexsomnia, also known as sleep sex or somnambulistic sexual behavior, refers to unintentional sexual behaviors or activities during sleep. Sexsomnia is a relatively new diagnosis. The term was coined by Shapiro and colleagues in 2003,[1] but cases of this condition have been reported in the literature for the past 3 decades.[2,3] Sexual behavior during sleep automatism can range from explicit vocalizations to touching or sexual intercourse, and in some cases even sexual assault or rape. It is non-rapid eye movement (NREM) parasomnia characterized by abnormal transitions between sleep and wake states. The second edition of the International Classification of Sleep Disorders (ICSD-2) discusses somnambulistic sexual activity in the context of disorders of arousal from NREM sleep.[4] Most commonly, NREM parasomnias arise from slow-wave sleep (SWS). Because of a relative lack of cortical control, partial arousals from this deep state of sleep can lead to uninhibited manifesta…
Post a Comment
Read more